Activating the power of your immune system.
Qu Biologics is developing a platform of new immunotherapeutic treatments. Our Site Specific Immunomodulators (SSIs) aim to activate the body’s immune system to reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases, such as Crohn’s disease.
More than 270 patients with advanced cancer and moderate-to-severe immune-related disease have been treated with Qu Biologics’ SSIs through a compassionate use program. The preliminary findings suggest some promising outcomes which support further research in controlled clinical trials.
Currently, we are recruiting for a Phase 1/2 clinical trial in Crohn’s disease. More information on this Crohn’s disease research trial can be found at www.qucrohnstrial.com.
Qu Biologics’ goal is to develop SSIs to improve the survival and quality of life of millions of people fighting cancer and the quality of life of people living with debilitating immune-related diseases such as Crohn’s disease, ulcerative colitis and rheumatoid arthritis.